=> s cytokine#

L1 230576 CYTOKINE#

=> s l1 (5a) (hybrid# or conjugat? or fusion? or chimer?)

L2 1796 L1 (5A) (HYBRID# OR CONJUGAT? OR FUSION? OR CHIMER?)

=> s l2 (5a) (interleukin-7 or il-7)

L3 28 L2 (5A) (INTERLEUKIN-7 OR IL-7)

=> d l3 1-28 bib ab

L3 ANSWER 1 OF 28 MEDLINE
AN 2002427395 IN-PROCESS
DN 22172984 PubMed ID: 12184921
TI Pre-pro-B Cell Growth-Stimulating Factor (PPBSF) Upregulates IL-7Ralpha
Chain Expression and Enables pro-B Cells to Respond to Monomeric IL-7.
AU Wei Chiju; Lai Laijun; Goldschneider Irving
CS Department of Pathology, School of Medicine, University of Connecticut
Health Center, Farmington, CT 06030-3105.
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2002 Jul) 22 (7) 823-32.
Journal code: 9507088. ISSN: 1079-9907.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20020820
Last Updated on STN: 20020820
AB Although pro-B cells are well represented in IL-7 knockout (KO) mice, they
express abnormally low concentrations of the interleukin-7 receptor
alpha-chain (IL-7Ralpha) and do not generate pre-B cells. Here, we
demonstrate that pro-B cells from IL-7 KO mice can be induced to generate
pre-B cells and immature B cells by exposure to recombinant IL-7 (rIL-7)
in vivo but not in vitro. Experiments in recombinant activation gene-1
(RAG-1) KO mice indicate that the in vitro unresponsiveness of IL-7(-/-)
pro-B cells to rIL-7 is unrelated to the absence of a functional pre-B
cell receptor (pre-BCR). Rather, it appears to be due to the suboptimal
expression of the IL-7Ralpha chain. Thus, IL-7(-/-) pro-B cells readily
respond to rIL-7 in vitro if IL-7Ralpha chain expression is first
upregulated by exposure to IL-7 in vivo or to IL-7(+/+) bone marrow (BM)
stromal cells or conditioned medium (CM) therefrom in vitro. Similar
results were obtained when pro-B cells from IL-7 KO mice were cultured on
IL-7(-/-) BM stromal cells in the presence of rIL-7. This suggested that
the recently described pre-pro-B cell growth-stimulating factor (PPBSF), a
self-assembling ***hybrid*** ***cytokine*** comprising ***IL***
- ***7*** and the stromal cell-derived hepatocyte growth factor
beta-chain (HGFbeta), is required to stimulate pro-B cells from
IL-7 KO
mice. This inference was verified by demonstrating that purified PPBSF
upregulates IL-7Ralpha chain expression on IL-7(-/-) pro-B cells in vitro
and enables them to respond to rIL-7 in a stepwise manner. We, therefore,
postulate that PPBSF is the operative form of IL-7 that normally induces
IL-7Ralpha(lo) pre-pro-B cells to proliferate and differentiate into
IL-7Ralpha(hi) pro-B cells, which then proliferate and differentiate into
pre-B cells on stimulation with monomeric IL-7.

L3 ANSWER 2 OF 28 MEDLINE
AN 2001517560 MEDLINE
DN 21448677 PubMed ID: 11564764
TI Cutting edge: Identification of a ***hybrid*** ***cytokine***
consisting of ***IL*** - ***7*** and the beta-chain of the hepatocyte growth factor/scatter factor.
AU Lai L; Goldschneider I
CS Department of Pathology, School of Medicine, University of Connecticut
Health Center, Farmington, CT 06030, USA.
NC AI 32752 (NIAID)
SO JOURNAL OF IMMUNOLOGY, (2001 Oct 1) 167 (7) 3550-4.
Journal code: 2985117R. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200112
ED Entered STN: 20010924
Last Updated on STN: 20020122
Entered Medline: 20011204
AB Pre-pro-B cell growth-stimulating factor (PPBSF) is a heterodimer of IL-7
and a 30-kDa cofactor. Unlike monomeric IL-7, PPBSF selectively induces
proliferation and differentiation of pre-pro-B cells and up-regulates
IL-7Ralpha-chain expression. Here we clone the PPBSF cofactor from bone
marrow stromal cells and identify it as a variant beta-chain of hepatocyte
growth factor (HGF), a pleiotropic cytokine homologous to plasminogen that
regulates cell growth, motility, and morphogenesis. We further demonstrate
that, in the presence of low m.w. heparin sulfate-derived
oligosaccharides, rHGFbeta combines with rIL-7 to form a biologically
active heterodimer having the properties of PPBSF. The results indicate
that PPBSF is a novel form of cytokine (hybrid cytokine) consisting of the
bioactive components of two unrelated cytokines. Based on its
heparin-binding and mitogenic properties, we postulate that the
HGFbeta-chain in PPBSF enables IL-7 to participate in cognate interactions
at the stromal cell surface and to transduce signals effectively at low
levels of IL-7R.

L3 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2002:593272 CAPLUS
DN 137:139125
TI Pre-pro-B cell growth-stimulating factor (PPBSF) upregulates IL-7R.alpha.

chain expression and enables pro-B cells to respond to monomeric IL-7
AU Wei, Chiju; Lai, Laijun; Goldschneider, Irving
CS Dept. of Pathology, School of Medicine, Univ. of Conneticut Health Center,
Farmington, CT, 06030-3105, USA
SO Journal of Interferon and Cytokine Research (2002), 22(7), 823-832
CODEN: JICRFJ; ISSN: 1079-9907
PB Mary Ann Liebert, Inc.
DT Journal
LA English
AB Although pro-B cells are well represented in IL-7 knockout (KO) mice, they
express abnormally low concns. of the interleukin-7 receptor .alpha.-chain
(IL-7R.alpha.) and do not generate pre-B cells. Here, we demonstrate that
pro-B cells from IL-7 KO mice can be induced to generate pre-B cells and
immature B cells by exposure to recombinant IL-7 (rIL-7) in vivo but not
in vitro. Expts. in recombinant activation gene-1 (RAG-1) KO mice
indicate that the in vitro unresponsiveness of IL-7-/- pro-B cells to
rIL-7 is unrelated to the absence of a functional pre-B cell receptor
(pre-BCR). Rather, it appears to be due to the suboptimal expression of
the IL-7R.alpha. chain. Thus, IL-7-/- pro-B cells readily respond to
rIL-7 in vitro if IL-7R.alpha. chain expression is first upregulated by
exposure to IL-7 in vivo or to IL-7+/+ bone marrow (BM) stromal cells or
conditioned medium (CM) there from in vitro. Similar results were
obtained when pro-B cells from IL-7 KO mice were cultured on IL-7-/- BM
stromal cells in the presence of rIL-7. This suggested that the recently
described pre-pro-B cell growth-stimulating factor (PPBSF), a
self-assembling ***hybrid*** ***cytokine*** comprising ***IL***
- ***7*** and the stromal cell-derived hepatocyte growth factor .beta.-chain (HGF.beta.), is required to stimulate pro-B cells from IL-7
KO mice. This inference was verified by demonstrating that purified PPBSF
upregulates IL-7R.alpha. chain expression on IL-7-/- pro-B cells in vitro
and enables them to respond to rIL-7 in a stepwise manner. We, therefore,
postulate that PPBSF is the operative form of IL-7 that normally induces
IL-7R.alpha.lo pre-pro-B cells to proliferate and differentiate into
IL-7R.alpha.hi pro-B cells, which then proliferate and differentiate into
pre-B cells on stimulation with monomeric IL-7.
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2002:31282 CAPLUS
DN 136:101106
TI Enhancement of antibody-cytokine fusion protein mediated immune responses
by combined treatment with immunocytokine uptake enhancing agents
IN Gillies, Stephen D.; Lan, Yan; Holden, Sylvia A.
PA Lexigen Pharmaceuticals Corp., USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002002143	A2	20020110	WO 2001-US20958	20010629
WO 2002002143	A3	20020718		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-215038P P 20000629
AB Disclosed are methods and compns. for treating tumors. Disclosed methods
and compns. enhance the uptake of immunocytokines into tumors, and are
based on a combination of an immunocytokine with an immunocytokine uptake
enhancing agent. Disclosed methods and compns. are particularly useful
for reducing tumor size and metastasis in a mammal.

L3 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:924005 CAPLUS
DN 136:49347
TI Chimeric binding agent comprising cytokine, linker and cytokine receptor
and uses in modulating receptor activity and therapy
IN Ross, Richard; Artymiuk, Peter; Sayers, Jon
PA Asterion Limited, UK
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001096565	A2	20011220	WO 2001-GB2645	20010618
WO 2001096565	A3	20020801		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW,

AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2000-14765 A 20000616
GB 2001-5969 A 20010310
GB 2001-6487 A 20010316
AB The invention provides a binding agent comprising a first part capable of
binding a ligand binding domain of a receptor linked to a second part
comprising a receptor binding domain wherein said binding agent modulates
the activity of the receptor. The inventors link growth hormone (GH),
through its C-terminal and a linker to the N-terminus of the SD100 domain
of growth hormone receptor (GHR). By varying the length of the linker
inventors define a mol. that has the flexibility to allow binding of GH
through site 1 to full length receptor at the cell surface. The invention
also relates to methods, vectors and host cells for prodn. of said chimeric binding agent.

L3 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:748030 CAPLUS
DN 135:302953
TI ***Hybrid*** ***cytokine*** of ***Il*** - ***7*** and .beta.-chain of hepatocyte growth factor
IN Goldschneider, Irving; Lai, Laijun
PA University of Connecticut, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001075140	A1	20011011	WO 2001-US10408	20010330

W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR
US 2002058791 A1 20020516 US 2001-823933 20010330
PRAI US 2000-193273P P 20000330
AB A hybrid cytokine comprising the .beta.-chain of hepatocyte growth factor
and IL-7, linked by a linker mol., having pre-pro-B growth stimulating
activity.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:712014 CAPLUS
DN 136:4515
TI Cutting edge: identification of a ***hybrid*** ***cytokine***
consisting of ***IL*** - ***7*** and the .beta.-chain of the hepatocyte growth factor/scatter factor
AU Lai, Laijun; Goldschneider, Irving
CS Department of Pathology, School of Medicine, University of Connecticut
Health Center, Farmington, CT, 06030, USA
SO Journal of Immunology (2001), 167(7), 3550-3554
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
AB Pre-pro-B cell growth-stimulating factor (PPBSF) is a heterodimer of IL-7
and a 30-kDa cofactor. Unlike monomeric IL-7, PPBSF selectively induces
proliferation and differentiation of pre-pro-B cells and up-regulates
IL-7R.alpha.-chain expression. Here the authors clone the PPBSF cofactor
from bone marrow stromal cells and identify it as a variant .beta.-chain
of hepatocyte growth factor (HGF), a pleiotropic cytokine homologous to
plasminogen that regulates cell growth, motility, and morphogenesis. The
authors further demonstrate that, in the presence of low mol. wt. heparin
sulfate-derived oligosaccharides, rHGF.beta. combines with rIL-7 to form a
biol. active heterodimer having the properties of PPBSF. Thus, PPBSF is a
novel form of cytokine (hybrid cytokine) consisting of the bioactive
components of 2 unrelated cytokines. Based on its heparin-binding and
mitogenic properties, the authors postulate that the HGF.beta.-chain in
PPBSF enables IL-7 to participate in cognate interactions at the stromal
cell surface and to transduce signals effectively at low levels of IL-7R.
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2000:227794 CAPLUS
DN 132:261102
TI Receptor-based cytokine antagonists and their production with recombinant
cells
IN Stahl, Neil; Yancopoulos, George D.
PA Regeneron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000018932	A2	20000406	WO 1999-US22045	19990922
WO 2000018932	A3	20001102		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2002012962 A1 20020131 US 1999-313942 19990519
AU 9964994 A1 20000417 AU 1999-64994 19990922
EP 1115876 A2 20010718 EP 1999-952942 19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
EP 1229047 A2 20020807 EP 2002-7831 19990922
EP 1229047 A3 20021002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY
JP 2002525119 T2 20020813 JP 2000-572379 19990922
NO 2001001513 A 20010525 NO 2001-1513 20010323
PRAI US 1998-101858P P 19980925
US 1999-313942 A 19990519
EP 1999-952942 A3 19990922
WO 1999-US22045 W 19990922
AB The present invention provides a fusion protein capable of binding a
cytokine to form a nonfunctional complex. It also provides a nucleic acid
sequence encoding the fusion polypeptide and methods of making and uses
for the fusion polypeptide. Thus, a chimeric gene encoding the
interleukin 1 binding domain of Plasmodium falciparum thrombospondin-
related protein fused to the interleukin 1 binding domain of human
interleukin 1 receptor fused to the IgG1 Fc domain was prepd. and
expressed in CHO cells. Administration of this "interleukin 1 trap" to
mice blocked increase in interleukin 6 upon administration of interleukin
1. The effects of this trapping persisted for at least 24 h.

L3 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1998:300462 CAPLUS
DN 128:320573
TI Chimeric cytokine receptors in lymphocytes
IN Greenberg, Philip D.; Nelson, Brad H.
PA Fred Hutchinson Cancer Research Center, USA
SO U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 43,389, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5747292	A	19980505	US 1994-244468	19940531
WO 9422914	A1	19941013	WO 1994-US3769	19940406

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE,
HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ,
PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
PRAI US 1993-43389 19930406
WO 1994-US3769 19940406
AB Recombinant polynucleotides are provided that encode chimeric cytokine
receptors. The chimeric cytokine receptors are useful for reducing
dependency of activated lymphocytes on T helper cells and/or growth
factors supplied by helper T cells. The chimeric receptor is comprised of
an extracellular domain derived from cytokine receptor A-R that binds
cytokine A, fused to a transmembrane and cytoplasmic domain derived from
cytokine receptor B-R that binds cytokine B. A chimeric receptor is
provided comprising a granulocyte/macrophage-colony-stimulating factor
receptor extracellular domain fused to an interleukin 2 receptor
transmembrane and cytoplasmic domain. When the chimeric receptor is
expressed in a lymphocyte it lessens the growth dependency of the
lymphocyte on cytokine B in the presence of cytokine A.

L3 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:593931 CAPLUS
DN 125:239372
TI Recombinant preparation of human c-mpl ligands (thrombopoietin) and fusion
proteins containing them for clinical use
IN Staten, Nicholas R.; Favara, Jean P.; Kahn, Larry E.; Baum, Charles M.;
Pegg, Lyle E.; Mckearn, John P.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9623888	A1	19960808	WO 1996-US830	19960201

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE
CA 2212006 AA 19960808 CA 1996-2212006 19960201
AU 9646585 A1 19960821 AU 1996-46585 19960201
EP 807181 A1 19971119 EP 1996-902169 19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE
JP 11500308 T2 19990112 JP 1996-523594 19960201
US 6254870 B1 20010703 US 1998-875533 19980130
PRAI US 1995-383035 A2 19950203
WO 1996-US830 W 19960201
AB A novel human c-mpl ligand (thrombopoietin)-encoding cDNA sequence has
been isolated and its amino acid sequence deduced. The cDNA sequence is
used for the prodn. of c-mpl ligands to be used in the treatment of

thrombocytopenia. A fragment of c-mpl (residues 1-153) can be used for
the prepn. of fusion proteins contg. a colony-stimulating factor selected
from GM-CSF, CSF-1, G-CSF, etc. for stimulating hematopoietic cell
differentiation and proliferation. Prepn. of c-mpl or fusion proteins
with transgenic BHK cells, Escherichia coli, or using the baculovirus
system was demonstrated.

L3 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:458055 CAPLUS
DN 125:112772
TI Chimeric cytokines and uses thereof
IN Strom, Terry B.; Zheng, Xin-Xiao; Steele, Alan
PA Beth Israel Hospital Association, USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9618412	A1	19960620	WO 1995-US16046	19951212
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6410008	B1	20020625	US 1994-355502	19941212
EP 793504	A1	19970910	EP 1995-943058	19951212
R: CH, DE, FR, GB, IT, LI, SE				
JP 11501506	T2	19990209	JP 1995-519191	19951212
US 6403077	B1	20020611	US 1997-968905	19971106

PRAI US 1994-355502 A 19941212
US 1995-431535 A 19950428
WO 1995-US16046 W 19951212
AB Disclosed are chimeric proteins having a cytokine fused to an enzymically
inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or
preventing a variety of conditions, including septic shock, granulomatous
disorders, Type I diabetes, and various cancers (e.g., multiple myeloma)
in a patient.

L3 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:452250 CAPLUS
DN 125:109098
TI Stable N-terminus-linked DTPA-protein compositions, their preparation, and
use in diagnosis and therapy
IN Litzinger, David C.; Ralph, Lloyd D.
PA Amgen Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9615816	A2	19960530	WO 1995-US15072	19951117
WO 9615816	A3	19960808		
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES,				
FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV,				
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
SK, TJ				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,				
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,				
NE, SN, TD, TG				
AU 9643667	A1	19960617	AU 1996-43667	19951117
AU 709012	B2	19990819		
EP 796113	A2	19970924	EP 1995-942444	19951117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10509179	T2	19980908	JP 1995-517016	19951117

PRAI US 1994-342481 19941117
WO 1995-US15072 19951117
AB Diethylenetriaminepentaacetic acid (DTPA)-protein compns. are disclosed in
which the chelating agent DTPA has been conjugated site-specifically to
the N-terminus of the protein, thereby providing a homogeneous and
well-defined product capable of forming complexes with a variety of
metallic radionuclides. The compns. of the present invention can be
produced in large quantities and retain full in vivo bioactivity, either
with or without chelated metallic radionuclide. The compns. may have
potential use in diagnosis, imaging, and/or treatment of leukemia and
related diseases. Prepn. and characterization of DTPA conjugates with
recombinant human G-CSF and with interleukin-2 are described.

L3 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1995:951242 CAPLUS
DN 124:84915
TI Fusion products of interleukin 3 with hematopoietic growth factors and
their manufacture for therapeutic use
IN Bauer, Christopher S.; Abrams, Mark Allen; Braford-Goldberg, Sarah Ruth;
Caparon, Marie Helena; Easton, Alan Michael; Klein, Barbara Kure; Mc,
Kearn John Patrick; Olins, Peter O.; Paik, Kumnan; Thomas, John Warren
PA G. D. Searle and Co., USA
SO PCT Int. Appl., 447 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 17

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9521254	A1	19950810	WO 1995-US1185	19950202
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,				
GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU,				

LV, MD, MG,
MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT,
UA, US
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
TD, TG
US 6057133 A 20000502 US 1994-192325 19940204
AU 9518356 A1 19950821 AU 1995-18356 19950202
AU 697433 B2 19981008
EP 742826 A1 19961120 EP 1995-910141 19950202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
BR 9506733 A 19970923 BR 1995-6733 19950202
JP 10502801 T2 19980317 JP 1995-520671 19950202
US 6022535 A 20000208 US 1995-469318 19950606
US 6030812 A 20000229 US 1995-468609 19950606
US 6361977 B1 20020326 US 1995-446872 19950606
NO 9603225 A 19960925 NO 1996-3225 19960801
FI 9603072 A 19960802 FI 1996-3072 19960802
US 6436387 B1 20020820 US 1996-762227 19961209
PRAI US 1994-192325 A2 19940204
US 1992-981044 B2 19921124
WO 1993-US11197 A2 19931122
WO 1995-US1185 W 19950202
US 1995-411795 A2 19950406
US 1995-446872 A2 19950606
AB Human interleukin-3 (hIL-3) variants fused with other colony stimulating
factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth
factors or IL-3 variants are described. These variants and fusion proteins are intended for use in the stimulation of hematopoiesis in support of chemotherapy of cancer, notably of leukemias and B-lymphomas.
The IL-3 variants may have 1-14 N- or 1-15 C-terminal deletions and have
4-26 addnl. amino acid substitutions. A linker peptide derived from an Ig
hinge region can be used to join the domains of the fusion protein and a
proteinase cleavage site may be incorporated into the linker region. The
construction of expression vectors for manuf. of these fusion proteins in
Escherichia coli is described. A no. of fusion proteins were tested and
found to show the biol. activities expected of both moieties.

L3 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1995:849313 CAPLUS
DN 123:254584
TI IL-3 variant hematopoiesis fusion protein
IN Bauer, Christopher S.; Abrams, Mark Allen; Braford-Goldberg, Sarah Ruth;
Caparon, Maire Helena; Easton, Alan Michael; Klein, Barbara Kure; Mc,
Kearn John Patrick; Olins, Peter O.; Paik, Kumnan; Thomas, John Warren
PA USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 17
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9521197 A1 19950810 WO 1995-US549 19950125
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,
MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT,
UA, US
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
TD, TG
US 5738849 A 19980414 US 1994-192299 19940204
AU 9516805 A1 19950821 AU 1995-16805 19950125
AU 700220 B2 19981224
EP 742796 A1 19961120 EP 1995-908514 19950125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 09508524 T2 19970902 JP 1995-520622 19950125
PRAI US 1994-192299 A1 19940204
US 1992-981044 B2 19921124
WO 1995-US549 W 19950125
US 1995-411796 A2 19950406
AB Provided are fusion mols. composed of human interleukin-3 (IL-3) variant
or mutant proteins (muteins) functionally joined to a second colony
stimulating factor (CSF), cytokine, lymphokine, interleukin, or IL-3
variant. These hIL-3 variants contain amino acid substitutions and may
also have amino acid deletions at both the N- and C-terminal. The invention also relates to pharmaceutical compns. contg. the fusion mols.
and methods for using them.

L3 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1995:721428 CAPLUS
DN 123:93346
TI Antitumor recombinant immunoconjugates
IN von Hoegen, Ilka; Hofmann, Uwe; Jaeggle, Carlota-Silvia; Strittmatter,
Wolfgang; Stadlmueller, Joerg; Matzku, Siegfried
PA Merck Patent G.m.b.H., Germany
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI EP 659439 A2 19950628 EP 1994-119712 19941214
EP 659439 A3 19961204
EP 659439 B1 20011024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU,

NL, PT, SE
AT 207366 E 20011115 AT 1994-119712 19941214
ES 2166368 T3 20020416 ES 1994-119712 19941214
AU 9481593 A1 19950629 AU 1994-81593 19941220
AU 688817 B2 19980319
CA 2138928 AA 19950625 CA 1994-2138928 19941222
NO 9404980 A 19950626 NO 1994-4980 19941222
JP 07223968 A2 19950822 JP 1994-320978 19941222
ZA 9410282 A 19950829 ZA 1994-10282 19941222
PL 178793 B1 20000630 PL 1994-306474 19941222
HU 70471 A2 19951030 HU 1994-3784 19941223
HU 219680 B 20010628
RU 2129018 C1 19990420 RU 1994-45281 19941223
CZ 289099 B6 20011114 CZ 1994-3306 19941227
PRAI EP 1993-120865 A 19931224
AB Fusion proteins which consist of a tumor-assocd. targeting element, preferentially a monoclonal antibody or a fragment thereof recognizing a mol. which is preferentially expressed on human tumor cells such as the human EGF receptor (EGFR), and a biol. active ligand such as a growth and/or differentiation factor or a cytokine, may be used to deliver the biol. active ligand to a specific target cell or tissue, e.g. in tumor therapy. Thus, tumor necrosis factor .alpha. cDNA was inserted at the end of the const. region portion of the DNA for the heavy chain of monoclonal antibody 425, directed to human A431 carcinoma cell line, in a pBluescript SK+-derived phagemid and cloned into eukaryotic expression vector pHCMV for expression in COS-7 cells. The fusion protein obtained from cell supernatants was cytotoxic to WEHI 164 cells in vitro.

L3 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1994:699132 CAPLUS
DN 121:299132
TI Chimeric cytokine receptors in lymphocytes
IN Greenberg, Philip D.; Nelson, Brad H.
PA Fred Hutchinson Cancer Research Center, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9422914	A1	19941013	WO 1994-US3769	19940406

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2160011 AA 19941013 CA 1994-2160011 19940406
AU 9466271 A1 19941024 AU 1994-66271 19940406
AU 695869 B2 19980827
EP 693084 A1 19960124 EP 1994-914054 19940406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
US 5747292 A 19980505 US 1994-244468 19940531
PRAI US 1993-43389 19930406
WO 1994-US3769 19940406
AB Recombinant polynucleotides are provided that encode chimeric cytokine receptors. The chimeric cytokine receptors are useful for reducing dependency of activated lymphocytes on T helper cells and/or growth factors supplied by helper T cells. The chimeric receptor is comprised of an extracellular domain derived from cytokine receptor A-R that binds cytokine A, fused to a transmembrane and cytoplasmic domain derived from cytokine receptor B-R that binds cytokine B. The figure depicts a chimeric receptor with a GM-GSF receptor extracellular domain fused to an IL 2 receptor transmembrane and cytoplasmic domain. When the chimeric receptor is expressed in a lymphocyte it lessens the growth dependency of the lymphocyte on cytokine B in the presence of cytokine A.

L3 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1994:154959 CAPLUS
DN 120:154959
TI Activation of oligomerizing receptors by using fused receptor ligands
IN Godowski, Paul J.
PA Genentech, Inc., USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9323550	A2	19931125	WO 1993-US4717	19930517
WO 9323550	A3	19940303		

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 5316921 A 19940531 US 1992-884811 19920518
US 5328837 A 19940712 US 1992-885971 19920518
EP 642585 A1 19950315 EP 1993-911350 19930517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 07508178 T2 19950914 JP 1993-503819 19930517
US 5580963 A 19961203 US 1994-194088 19940209
US 5684136 A 19971104 US 1995-435501 19950505
US 5763584 A 19980609 US 1995-435764 19950505

US 5770704 A 19980623 US 1997-792078 19970131
PRAI US 1992-884811 A 19920518
US 1992-885971 A 19920518
US 1992-950572 A2 19920921
WO 1993-US4717 W 19930517
US 1993-87784 B1 19930713
US 1994-268880 B3 19940630
US 1995-423291 B1 19950417
AB The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their resp. receptors inducing receptor oligomerization. Human hepatocyte growth factor (huHGF) analogs [Glu-494]huHGF and [Ser-673,Ser-692]huHGF were prepd. with recombinant 293 cells. These analogs were not mitogenic. These same analogs were prepd. as fusion proteins with amino acids 216-443 of the IgG-.gamma.1 heavy chain using 293 cells. The mitogenic activity was completely restored.

L3 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1993:492290 CAPLUS
DN 119:92290
TI Chimeric mammals with human hematopoietic cells
IN Dick, John E.; Williams, Douglas E.; Lapidot, Tsvee
PA Immunex Corp., USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9309792	A1	19930527	WO 1992-US9913	19921119
W: AU, CA, FI, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
US 6353150	B1	20020305	US 1991-797493	19911122
AU 9331781	A1	19930615	AU 1993-31781	19921119
EP 625907	A1	19941130	EP 1993-900531	19921119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				

PRAI US 1991-797493 A 19911122
WO 1992-US9913 A 19921119
AB A chimeric mammal is disclosed which has a stable bone marrow graft of human hematopoietic cells capable of differentiating into multiple lineages of human mature cells, wherein .gtoreq.30% of the hematopoietic cells in the mammal's bone marrow are of human origin. The method comprises sublethally irradiating an immunodeficient mammal, infusing human hematopoietic cells into the mammal, and administering an effective amt. of human mast cell growth factor and a human GM-CSF/interleukin-3 fusion protein to promote engraftment of human cells within the chimeric mammal's bone marrow. The method was demonstrated in SCID (severe combined immune deficiency) mice.

L3 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1993:183439 CAPLUS
DN 118:183439
TI Noncytolytic toxin conjugates for therapeutics
IN Morgan, Alton Charles, Jr.; Abrams, Paul G.
PA Neorx Corp., USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9304191	A1	19930304	WO 1992-US6823	19920813
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				

PRAI US 1991-745158 19910815
AB Conjugates are disclosed which are useful for modifying target cell functions to achieve therapeutic results. Conjugates may include a noncytolytic toxin that does not directly inhibit protein synthesis and is capable of operating through an existing cellular metab. signalling mechanism conjugated to a targeting moiety that constitutes a ligand recognized by the target cell receptor involved in that existing signalling mechanism. Alternatively, the conjugates may include a toxin domain capable of directly impacting a target cell metabolic process (e.g. catalyzing conversion of ATP to cAMP) or acting on a substrate implicated in such a process (e.g. actin) conjugated with a targeting moiety specific for the target cell population. Methods of using the conjugates are also discussed. In mixed lymphocyte reaction studies with cholera holotoxin and cholera toxin B oligomer, the domain responsible for inhibition of proliferation was assocd. with the toxin's enzymic activity and likely the A1 subunit. Construction of a cholera toxin A1/interleukin-2 conjugate for abrogation of transplant rejection is described, as is modification of retargeted toxin to reduce immunogenicity.

L3 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1992:610644 CAPLUS
DN 117:210644
TI Interleukin-3 fusion proteins for stimulation of hematopoiesis
IN Schendel, Paul
PA Genetics Institute, Inc., USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9204455 A1 19920319 WO 1991-US6186 19910829
W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
CA 2089553 AA 19920301 CA 1991-2089553 19910829
AU 9189174 A1 19920330 AU 1991-89174 19910829
AU 651152 B2 19940714
EP 546124 A1 19930616 EP 1991-920109 19910829
EP 546124 B1 19980701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 06500116 T2 19940106 JP 1991-518431 19910829
JP 3149182 B2 20010326
AT 167896 E 19980715 AT 1991-920109 19910829
ES 2118756 T3 19981001 ES 1991-920109 19910829
US 5883230 A 19990316 US 1996-658762 19960605
PRAI US 1990-575003 A 19900829
WO 1991-US6186 A 19910829
US 1993-57198 B1 19930505

AB Fusion proteins of interleukin 3 and other lymphokines for use as stimulators of hematopoiesis are described. Chimeric genes for fusion proteins were constructed by std. methods; in some cases a connecting peptide was introduced between the two domains. A fusion protein of interleukins 3 and 11 was manufd. by expression of the chimeric gene in Escherichia coli. The protein was tested for stimulation of megakaryocyte formation in blood clots. The fusion protein (1 unit interleukin 3, 5 units interleukin 11/mL) yielded 26 megakaryocyte colonies/clot; vs. 14 for the activities of the two non-fused proteins.

L3 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1992:565256 CAPLUS
DN 117:165256
TI Fusion proteins containing constant regions of immunoglobulins, their production and use
IN Lauffer, Leander; Oquendo, Patricia; Zettlmeissl, Gerd; Seed, Brian
PA Behringwerke A.-G., Germany; General Hospital Corp.
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP 464533 A1 19920108 EP 1991-110307 19910622
EP 464533 B1 19980729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
EP 835939 A2 19980415 EP 1997-120664 19910622
EP 835939 A3 19980422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
AT 169030 E 19980815 AT 1991-110307 19910622
ES 2120949 T3 19981116 ES 1991-110307 19910622
CA 2045869 AA 19911229 CA 1991-2045869 19910627
AU 9179357 A1 19920102 AU 1991-79357 19910627
AU 655421 B2 19941222
JP 05247094 A2 19930924 JP 1991-183772 19910628
JP 2002201200 A2 20020716 JP 2001-319607 19910628
US 2001053539 A1 20011220 US 1999-286288 19990406
PRAI DE 1990-4020607 A 19900628
US 1990-581703 B1 19900913
EP 1991-110307 A3 19910622
JP 1991-183772 A3 19910628
US 1993-13229 B1 19930201
US 1994-293603 A3 19940822

AB Sol. fusion proteins of human proteins that do not belong to the Ig family fused to Ig fragments, are described for use in diagnosis and therapy. The Ig-derived moiety makes these proteins are easy to purify by affinity chromatog. The presence of the Ig fragment does not appear to unfavorably affect the biol. activity of the human protein, so the fusion proteins could be used without removal of the Ig domain(s). Plasmids encoding fusion proteins between human IgG1 hinge, CH2, and CH3-contg. protein and human thromboplastin, IL-4 receptor, and erythropoietin were prepd., and the chimeric genes for the first two fusion proteins were expressed in COS cells. These proteins, purified with protein A-Sepharose, displayed the same biol. activity as the nonfused parent proteins.

L3 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1992:19660 CAPLUS
DN 116:19660
TI Chimeric antibodies with receptor-binding ligands in place of their constant region
IN Morrison, Sherie L.; Shin, Seung Uon
PA Columbia University, USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9114438 A1 19911003 WO 1991-US1844 19910320
W: AU, CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
CA 2078689 AA 19910921 CA 1991-2078689 19910320
AU 9175582 A1 19911021 AU 1991-75582 19910320
AU 654811 B2 19941124
EP 521985 A1 19930113 EP 1991-906955

19910320
EP 521985 B1 19970924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 05506574 T2 19930930 JP 1991-507276 19910320
JP 3319594 B2 20020903
AT 158615 E 19971015 AT 1991-906955 19910320
PRAI US 1990-496409 A2 19900320
WO 1991-US1844 A 19910320
AB A modified chimeric monoclonal antibody (MAb) comprises 2 shorter polypeptides functioning as the light chains of the Ab and 2 longer polypeptides functioning as heavy chains. The longer chains have a variable region characteristic of a 1st mammal and a const. region characteristic of a 2nd mammal; at least a portion of the const. region is replaced with a receptor-binding ligand. Immunol. reactive complexes and chimeric polypeptides are also disclosed, as are recombinant methods of producing chimeric MAbs, immunol. reactive complexes, and chimeric polypeptides. The MAbs are useful in pharmaceuticals for delivering drugs (e.g. in treatment of neoplasms) and in detecting cells having a receptor targeted by the ligand at the const. region of the MAb. The cDNA encoding the VH, CH1, hinge, and 1st amino acid of CH2 from a chimeric mouse/human IgG3 anti-dansyl antibody was joined to a cDNA encoding rat insulin-like growth factor 1 (IGF1) immediately 3' to the leader sequence of IGF1. The chimeric heavy chain gene vector and a vector encoding an anti-dansyl chimeric K light chain were introduced into myeloma P3X63Ag8.653. The chimeric IgG3-protein was produced and secreted at 30 .mu.g/106 cells/24h, had specificity for the dansyl antigen, and bound the IGF1 receptors of human lymphoblast IM-9. The activity and binding was similar but reduced compared with human IGF1.

L3 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1991:242034 CAPLUS
DN 114:242034
TI Multifunctional macrophage-colony stimulating factor (M-CSF) proteins and genes encoding therefor
IN Ralph, Peter; Martin, George; Piatak, Michael; Larrick, James W.
PA Cetus Corp., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9012877	A1	19901101	WO 1990-US1673	19900330
W: AU, CA, FI, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9053557	A1	19901116	AU 1990-53557	19900330
US 5567611	A	19961022	US 1994-354456	19941212
US 6022953	A	20000208	US 1995-429940	19950427

PRAI US 1989-340228 19890419
WO 1990-US1673 19900330
US 1992-995338 19921221
US 1994-354456 19941212
AB Chimeric genes encoding M-CSF fusion proteins are constructed and expressed in mammalian cells. The recombinant proteins, which contain M-CSF fused to other CSFs, interleukins, interferons, tumor necrosis factors, erythropoietin, thrombopoietin, or toxins display biol. activities characteristic of both of the constituent proteins.

L3 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1991:141413 CAPLUS
DN 114:141413
TI Conjugates of antibodies and biological response modifiers, such as tumor necrosis factor, for delivery to target tissues and cells
IN Rosenblum, Michael G.; Wellen, Clyde William
PA Research Development Foundation, USA
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 396387	A2	19901107	EP 1990-304734	19900501
EP 396387	A3	19910403		
EP 396387	B1	19931222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 9002949	A	19920226	ZA 1990-2949	19900419
CA 2015060	AA	19901105	CA 1990-2015060	19900420
AU 9053795	A1	19901108	AU 1990-53795	19900423
AU 645747	B2	19940127		
IL 94167	A1	19970218	IL 1990-94167	19900423
JP 02306923	A2	19901220	JP 1990-115709	19900501
AT 98873	E	19940115	AT 1990-304734	19900501
ES 2060947	T3	19941201	ES 1990-304734	19900501
NO 9001986	A	19901106	NO 1990-1986	19900504
CN 1047035	A	19901121	CN 1990-102690	19900505
CN 1072505	B	20011010		

PRAI US 1989-348237 A 19890505
EP 1990-304734 A 19900501
AB Antibody-biol. response modifier conjugates are provided for delivery of the biol. response modifier, e.g. a lymphokine or cytokine, to target tissues and cells. A method of treating diseases by administration of the above conjugates is also provided. Thus, tumor necrosis factor (TNF) was purified, reacted with iminethiolane, and then conjugated with an N-succinimidyl-3-(2-pyridylthio)propionate-modified monoclonal antibody (MAb) against a melanoma membrane antigen. The purified

MAb-TNF conjugate
bound to antigen pos. human melanoma cells to the same extent as native
MAb. The conjugate was more active than free TNF when tested as a cell
growth inhibitor with the antigen-pos. cultured human melanoma cells.

L3 ANSWER 25 OF 28 USPATFULL
AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly colon cancer, are disclosed. Illustrative compositions
comprise one or more colon tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly colon cancer.

L3 ANSWER 26 OF 28 USPATFULL
AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002132237 A1 20020919
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L3 ANSWER 27 OF 28 USPATFULL
AN 2002:136553 USPATFULL
TI Treatment regimes featuring an IL-10-containing chimeric polypeptide
IN Strom, Terry B., Brookline, MA, United States
Zheng, Xin Xiao, Brookline, MA, United States
Steele, Alan, Wellesley, MA, United States
PA Beth Israel Hospital Association, Boston, MA, United States (U.S.
corporation)
PI US 6403077 B1 20020611
AI US 1997-968905 19971106 (8)
RLI Continuation of Ser. No. US 1995-431535, filed on 28 Apr 1995, now
abandoned Continuation-in-part of Ser. No. US 1994-355502, filed on 12
Dec 1994
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mertz, Prema
LREP Fish & Richardson P.C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1171
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are chimeric proteins having a cytokine fused to an
enzymatically inactive polypeptide which increases the circulating
half-life of the cytokine. The chimeric proteins are useful for
treating, inhibiting, or preventing a variety of conditions, including
septic shock, granulomatous disorders, Type I diabetes, and various
cancers (e.g., multiple myeloma) in a patient.

L3 ANSWER 28 OF 28 USPATFULL
AN 2002:113045 USPATFULL
TI ***Hybrid*** ***cytokine*** of ***IL*** - ***7*** and
beta-chain of hepatocyte growth factor
IN Goldschneider, Irving, Avon, CT, UNITED STATES
Lai, Laijun, Newington, CT, UNITED STATES
PI US 2002058791 A1 20020516
AI US 2001-823933 A1 20010330 (9)
PRAI US 2000-193273P 20000330 (60)
DT Utility
FS APPLICATION
LREP CUMMINGS AND LOCKWOOD, GRANITE SQUARE, 700 STATE STREET, P O BOX 1960,
NEW HAVEN, CT, 06509-1960
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1256
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A hybrid cytokine comprising the B-chain of hepatocyte growth factor and
IL-7, linked by a linker molecule, having pre-pro-B growth stimulating

activity.